Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients

AIDS

Volumn 12, Issue 15, 1998, Pages 1999-2005

  Raffi, François ^a,h   Reliquet, Véronique ^a   Auger, Sylvie ^a   Besnier, Jean Marc ^b   Chennebault, Jean Marie ^c   Billaud, Eric ^a   Michelet, Christian ^d   Perre, Philippe ^e   Lafeuillade, Alain ^f   May, Thierry ^g   Billaudel, Sylviane ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e CHD   (France)

^f Toulon General Hospital   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h HÔTEL DIEU   (France)

Author keywords

AIDS; Combination therapy; Didanosine; HIV; Neuropathy; Stavudine

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; STAVUDINE; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; VIREMIA; VIRUS LOAD;

EID: 7844223617     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00011     Document Type: Article

References (34)

1. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
2. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
4. Panel on Clinical Practices for Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Fed Register November 5, 1997, 1-37.
5. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997, 349:1408-1409.
6. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327:581-587.
7. National Institute of Allergy and Infectious Diseases, AIDS Clinical Trials Group: Executive Summary; ACTG 152. Bethesda: NIAID, ACTG; 28 February 1996.
8. Pavia AT, Gathe I, BMS-019 Study Group Investigators: Clinical efficacy of stavudine compared to zidovudine in ZDV-pretreated HIV positive patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract 1169].
9. Lin PF, Samanta H, Rose RE, et al.: Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994, 170:1157-1164.
10. Sommadosi JP: Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. J Infect Dis 1995, 171 (suppl 2):S88-S92.
11. Brancovan V, Tarantini K, Detems R, et al.: The synergistic activity of a purine and a pyrimidine nucleoside analog, ddl and d4T. V International Conference on AIDS. Montreal, June 1989 [abstract MCP128].
12. Merrill DP, Moonis M, Chou T-C, Hirsch MS: Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996, 173:55-364.
13. 3 and who are not eligible for a treatment with ZDV. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 553].
14. Seifert RD, Stewart MB, Sramek JJ, et al.: Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994, 38:405-410.
15. Gao WY, Johns DG, Chokekuchai S, Mitsuya H: Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995, 92:8333-8337.
16. Pollard R, Peterson D, Hardy D, et al.: Stavudine (d4T) and didanosine (ddl) combination therapy in HIV-infected subjects: analysis of antiviral effect and safety in a randomized double-blind study. 10th International Conference on Antiviral Research. Atlanta, April 1997 [abstract 31].
17. Browne MJ, Mayer KH, Chafee SBD, et al.: 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS-related complex: a phase I trial. J Infect Dis 1993, 167:21-29.
18. Murray HW, Squires KE, Weiss W, et al.: Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Infect Dis 1995, 171 (suppl 2):S123-S130.
19. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al.: Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995, 171 (suppl 2):S131-S139.
20. Spruance SL, Pavia AT, Mellors JW, et al.: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med 1997, 126:355-363.
21. Sommadossi JP, Valantin MA, Zhou XJ, et al.: Intracellular phosphorylation of stavudine and 3TC correlates with their antiviral activity in naive and zidovudine experienced HIV-infected patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 362].
22. Husson RN, Shirasaka T, Butler KM, Pizzo PA, Mitsuya H: High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr 1993, 123:9-16.
23. Shirasaka T, Yarchoan R, O'Brien M, et al.: Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993, 90:562-566.
24. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE: Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994, 169:411-413.
25. Quigg M, Rebus S, France AJ, et al.: Mutations associated with zidovudine resistance in HIV-1 among recent seroconverters [letter]. AIDS 1997, 11:835-836.
26. Mayers DL, Yerly S, Perrin L, et al.: Prevalence of AZT-resistant HIV-1 in persons seroconverting in Switzerland, Australia and the United States between 1988 and 1994. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, October 1994 [abstract LBA/11].
27. Mayers DL, Japour AJ, Arduino JM, et al.: Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 1994, 38:307-314.
28. Saravolatz LD, Winslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
29. Winters MA, Shafer RW, Jellinger RA, et al.: Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997, 41:757-762.
30. Soriano V, Dietrich U, Villalba N, et al.: Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997, 11:696-697.
31. Griffith BP, Brett-Smith H, Kim G, et al.: Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 1996, 175:1252-1255.
32. Coakley E, Gillis J, Pedneault L, Dunkle L, Hammer S: Susceptibilities of HIV-1 isolates derived from patients treated with didanosine (ddl) and stavudine (d4T) in combination. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 575].
33. Auger S, Ferre-Aubineau V, Monpeho S, et al.: Genotypic and phenotypic susceptibility of HIV-1 isolates from patients treated with stavudine-didanosine combination. 11th International Conference on Antiviral Research. San Diego, April 1998 [abstract 77].
34. Maxson CJ, Greenfield SM, Turner JL: Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992, 87:708-713.